Shareholders' Equity (Deficit) (Tables)

12 Months Ended

Nov. 30, 2013

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense by type of award was as follows:

	Year Ended
	2013		2012		2011
	(In millions)
Stock appreciation rights (“SARS”)	$	9.4	$	2.7	$	0.4
Stock options		0.3		0.8		0.9
Restricted stock, service-based		2.3		2.2		1.7
Restricted stock, performance-based		2.1		0.8		0.7
Total stock-based compensation expense	$	14.1	$	6.5	$	3.7

Summary of Stock Appreciation Rights

A summary of the status of the Company’s SARS as of November 30, 2013 and changes during fiscal 2013 is presented below:

	SARS (In thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value (In millions)
Outstanding at November 30, 2012		1,529		$	10.47
Granted		73			13.17
Exercised		(138	)		7.92
Cancelled		(7	)		4.95
Outstanding at November 30, 2013		1,457		$	10.88		3.6	$	11.1
Exercisable at November 30, 2013		1,366		$	10.99		3.4	$	10.3
Expected to vest at November 30, 2013		89		$	9.18		5.6	$	0.8

Schedule of Stock Options Activity

A summary of the status of the Company’s stock options as of November 30, 2013 and changes during fiscal 2013 is presented below:

	Stock Options (In thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)		Intrinsic Value (In millions)
Outstanding at November 30, 2012		849		$	5.87
Exercised		(93	)		7.39
Cancelled		(125	)		6.30
Outstanding at November 30, 2013		631		$	5.57		4.2	$	8.1
Exercisable at November 30, 2013		532		$	5.48		4.1	$	6.8
Expected to vest at November 30, 2013		99		$	6.01		4.3	$	1.2

Summary of Range of Exercise Prices and Weighted-Average Exercise Prices for Options Outstanding

The following table summarizes the range of exercise prices and weighted-average exercise prices for options outstanding as of November 30, 2013 under the Company’s stock option plans:

			Outstanding
Year Granted	Range of Exercise Prices		Stock Options Outstanding (In thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)
2004	$	10.92		20	$	10.92		0.2
2009	$	4.54		133	$	4.54		5.6
2010	$	4.91 – $7.14		371	$	5.51		3.7
2011	$	6.01		100	$	6.01		4.3
2012	$	6.00		7	$	6.00		8.2
				631

Restricted Stock, Service-Based [Member]

Summary of Restricted Stock Units

The following is summary of the status of the Company’s service-based restricted stock as of November 30, 2013 and changes during fiscal 2013:

	Service Based Restricted Stock (In thousands)			Weighted Average Grant Date Fair Value
Outstanding at November 30, 2012		638		$	6.41
Granted		294			15.47
Vested		(374	)		6.99
Canceled		(14	)		6.09
Outstanding at November 30, 2013		544		$	10.91
Expected to vest at November 30, 2013		523		$	10.91

Performance-Based Restricted Stock [Member]

Summary of Restricted Stock Units

The following is a summary of the status of the Company’s performance-based restricted stock as of November 30, 2013 and changes during fiscal 2013:

	Performance Based Restricted Stock (In thousands)			Weighted Average Grant Date Fair Value
Outstanding at November 30, 2012		630		$	6.33
Granted		293			17.44
Vested		(63	)		5.12
Cancelled		(37	)		9.32
Outstanding at November 30, 2013		823		$	10.42
Expected to vest at November 30, 2013		773		$	9.95

Stock Options [Member]

Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options

The fair value of stock options was estimated using a Black-Scholes Model with the following weighted average assumptions:

	Year Ended
	2012			2011
Expected life (in years)		7.0			7.0
Volatility		57.47	%		57.19	%
Risk-free interest rate		1.54	%		2.53	%
Dividend yield		0.00	%		0.00	%

Stock Appreciation Rights [Member]

Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options

The fair value of SARS was estimated using a Black-Scholes Model with the following weighted average assumptions:

	Year Ended
	2013			2012			2011
Expected life (in years)		3.6			3.7			4.4
Volatility		44.30	%		55.47	%		62.60	%
Risk-free interest rate		0.84	%		0.51	%		0.91	%
Dividend yield		0.00	%		0.00	%		0.00	%